Drugs / Allogeneic Cartibeads
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06897111 | Jun 2024 → Jul 2025 overdue | — | Vanarix SA | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Allogeneic Cartibeads | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06897111 ↗ |
| Known as | allogenic Cartibeads | “investigate the safety and feasibility of implanting allogeneic cartilage mini-grafts (or allogenic Cartibeads) into cartilage defects in the knee.” NCT06897111 ↗ |
| Modality | Cell therapy | “Allogeneic Cartibeads are engineered from allogeneic articular chondrocytes (from a donor's cartilage cells).” NCT06897111 ↗ |
| Route | Other | “by minimally invasive surgery (arthroscopy or mini arthrotomy)” NCT06897111 ↗ |